CLL patients: Diagnostic difficulties, treatment confusion with COVID-19April 19, 2021COVID-19 UpdatesHematologic Malignancies
COVID-19 vaccine failure in patients with blood cancersApril 14, 2021COVID-19 UpdatesHematologic MalignanciesOncology
Steroids can be stopped in some older multiple myeloma patientsApril 1, 2021Multiple MyelomaHematologic MalignanciesGeriatrics
First CAR T-cell therapy for multiple myeloma: AbecmaMarch 29, 2021Multiple MyelomaHematologic Malignancies
Concern over response to COVID-19 in patients with blood cancersJanuary 12, 2021COVID-19 UpdatesOncologyHematologic Malignancies
Sequential Targeted Treatment for a Geriatric Patient with Acute Myeloid Leukemia with Concurrent FLT3-TKD and IDH1 MutationsJanuary 7, 2021Hematologic MalignanciesAMLOncology
Study found dual-targeted CAR T highly active against relapsed/refractory multiple myelomaDecember 15, 2020Multiple MyelomaHematologic MalignanciesOncology
Synthetic lethality: Triple combination is a viable strategy for B-cell malignanciesDecember 11, 2020Hematologic Malignancies
Highly effective in Ph-negative B-cell ALL: Hyper-CVAD with sequential blinatumomabDecember 11, 2020Hematologic Malignancies
Patients with lung and blood cancers most vulnerable to COVID-19December 10, 2020COVID-19 UpdatesLung CancerHematologic Malignancies
Extended virus shedding after COVID-19 in some patients with cancerDecember 10, 2020COVID-19 UpdatesMultiple MyelomaMyelodysplastic SyndromeHematologic Malignancies
Fixed duration ibrutinib/venetoclax appears feasible for some CLL/SLL patientsDecember 6, 2020Hematologic Malignancies
Neoadjuvant immunotherapy combo produces high response rate in melanomaNovember 25, 2020MelanomaOncologyHematologic Malignancies
